Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004142 · ClinicalTrials.gov registry record · Phase 2
Radiofrequency Ablation Followed By Hepatic Artery Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT00004142: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00004142 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 40 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00004142, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
RATIONALE: Radiofrequency ablation may be able to shrink or destroy cancer cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemotherapy delivered directly into the blood vessels of the liver may prevent new tumors from growing. Combining these therapies may be an effective treatment for colorectal cancer that has spread to the liver. PURPOSE: Phase II trial to study the effectiveness of radiofrequency ablation followed by chemotherapy delivered directly into the blood vessels of the liver in treating patients who have colorectal cancer that has spread to the liver.
Interventions
- DRUG Fluorouracil (5-FU)
- DRUG Floxuridine
- PROCEDURE Radiofrequency ablation
- PROCEDURE Conventional surgery
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 1998-08-05 |
| Est. Completion | 2003-12-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004142
The ClinicalTrials.gov registry entry for NCT00004142 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Fluorouracil (5-FU) is the first listed.
NCT00004142 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00004142 about?
NCT00004142 is a clinical study titled "Radiofrequency Ablation Followed By Hepatic Artery Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver". RATIONALE: Radiofrequency ablation may be able to shrink or destroy cancer cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemotherapy delivered directly into the blood vessels of the liver may prevent new tumors from growing. Comb...
What is the current status of trial NCT00004142?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 1998-08-05. Estimated completion is 2003-12-09.
What interventions are being tested in trial NCT00004142?
The interventions under investigation include: Fluorouracil (5-FU) (DRUG), Floxuridine (DRUG), Radiofrequency ablation (PROCEDURE), Conventional surgery (PROCEDURE).
Who is sponsoring clinical trial NCT00004142?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.